New study examines bleeding treatment in blood thinner patients

NCT ID NCT05898412

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 217 Dutch patients who were hospitalized with serious bleeding while taking a type of blood thinner called a factor Xa inhibitor. All patients received a drug called andexanet alfa to reverse the bleeding. Researchers wanted to learn more about the patients' characteristics and what happened after treatment, including any blood clots. The study is based on past medical records from about 10 hospitals in the Netherlands.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: andexanet alfa
What this could lead to: If successful, this study could help doctors better understand which patients might benefit most from andexanet alfa and how to use it safely.
What could go wrong: This is a small, retrospective study that only looks back at past data. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMORRHAGE

Contacts and locations

Locations

Research Site

Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.